# Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 Canonical URL: https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-augu-562a4f56 Ticker: ACAD Company: ACADIA Pharmaceuticals Inc. Source: ACADIA Pharmaceuticals Inc. Published: 2026-07-15 20:05 EST Original Source URL: https://acadia.com/media/news-releases/ ## Summary Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here . Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes ## Article Body Home News & Media News Releases Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 July 15, 2026 General Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time SAN DIEGO—(BUSINESS WIRE)— Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here . Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X . Source: Acadia Pharmaceuticals Inc. ## Recent Company News - 2026-07-20 13:05 EST — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) — Source: ACADIA Pharmaceuticals Inc. - 2026-07-15 20:05 EST — [Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-augu-562a4f56) — Source: ACADIA Pharmaceuticals Inc. - 2026-07-06 13:04 EST — [Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer-1598bf7e) — Source: ACADIA Pharmaceuticals Inc. - 2026-06-26 10:49 EST — [DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP](https://biopharmsignal.com/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-chmp-b5e699e2) — Source: ACADIA Pharmaceuticals Inc. - 2026-05-06 20:05 EST — [Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-reports-first-quarter-2026-financial-results-and-reaffirm-f524e802) — Source: ACADIA Pharmaceuticals Inc. ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)